Physician profile
William L Ward
NPI 1023093432
$4,425.58
in general payments reported to CMS, 2019-2025
17 companies · $52.72 in 2025
The $52.72 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $70.13 · 2021: $18.08 · 2022: $73.85 · 2023: $3,970 · 2024: $43.47 · 2025: $52.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,000 · Travel and Lodging: $864 · Food and Beverage: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,000.00 |
| Travel and Lodging | $863.70 |
| Food and Beverage | $202.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,970.34 | 2023 | Ion, Da Vinci Surgical System |
| Genentech USA, INC. | $73.54 | 2019-2020 | |
| Glaxosmithkline, LLC. | $69.00 | 2019-2024 | Nucala |
| Astrazeneca Pharmaceuticals LP | $47.36 | 2024-2025 | Fasenra, Airsupra |
| Abiomed | $45.16 | 2022 | |
| Mallinckrodt Enterprises LLC | $31.37 | 2019 | |
| Merck Sharp & Dohme LLC | $24.85 | 2025 | Zerbaxa |
| Jazz Pharmaceuticals INC. | $20.08 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.82 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.24 | 2020 | |
| United Therapeutics Corporation | $18.08 | 2021 | |
| Covidien LP | $15.75 | 2019 | |
| Organogenesis INC. | $15.41 | 2022 | |
| Circassia INC. | $15.39 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.44 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $13.47 | 2019 | |
| Boston Scientific Corporation | $13.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.